Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

Autor: Jose Nicolau, Victor Aboyans, Robert Storey, Jacek Kubica, Miguel Urina, Thomas Muenzel, Andrzej Lubiński, Peter Sinnaeve, ELENA BOBESCU, Antonio Fernandez-Ortiz, Ahmed Abdel-Latif, GABRIELA CIOCA, Bassem A. Samad, Philippe Gabriel STEG, Richard Nethononda, Lesia Rasputina, Murat Kazim Ersanli, Mariya Derevyanchenko, Arie Van Dijk, Sergey Nedogoda, Silvia Valbuena-Lopez, Fernando Lanas, Tomas Janota, Bas Kietselaer, Meyer ELBAZ, Eduardo Costa Duarte Barbosa, R. David Anderson, Piotr Ponikowski, Mara Rubino, Diego Rizzotti, Andriy Bazylevych, Maya Safarova, Mikhail Statsenko, Giuseppe Patti, Fernando Manzur, Sergey Golitsyn, Larisa Yena, William Wijns, Andrzej Budaj

Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2015, 372 (19), pp.1791-1800. ⟨10.1056/NEJMoa1500857⟩
The New England journal of medicine

International audience; BACKGROUND:The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with establ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb3e1405e855c1d5a47edfa42b1cd87a
https://hal.archives-ouvertes.fr/hal-01934996